Skip to main content

Table 1 Demographics and baseline characteristics (combined b.i.d. and t.i.d. dosing)

From: A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis

Demographics

Placebo (n = 18)

GSK2982772 (n = 33)

Age, years (mean [SD])a

53.1 (7.28)

54.8 (10.72)

Sex, n (%)

 Female

15 (83)

27 (82)

 Male

3 (17)

6 (18)

BMI, kg/m2 (mean [SD])

26.5 (4.35)

27.8 (4.48)

Ethnicity, n (%)

 Hispanic or Latino

0

2 (6)

 Not Hispanic or Latino

18 (100)

31 (94)

Race detail

 American Indian or Alaskan native

0

1 (3)

 White—White/Caucasian/European Heritage

18 (100)

32 (97)

Time since formal diagnosis of RA, years

 Mean (SD)

4.5 (3.27)

7.3 (7.24)

 Median (min, max)

3.9 (0.6, 12.9)

4.4 (0.4, 31.1)

Time since onset of first musculoskeletal symptoms, years

 Mean (SD)

6.6 (4.30)

9.5 (8.44)

 Median (min, max)

5.5 (2.1, 14.4)

7.8 (0.6, 33.1)

Baseline medical conditions, n (%)

 Cardiovascular risk factors

8 (44)

12 (36)

 Other risk factors

11 (61)

19 (58)

Baseline (day 1) DAS28-CRP

 Mean (SD)

5.4 (1.17)

5.2 (0.76)

 Median (min, max)a

5.5 (1.9, 7.2)

5.1 (3.7, 7.1)

Baseline (day 1) CRP

 Mean (SD)

19.8 (15.52)

14.4 (19.47)

 Median (min, max)a

15.1 (1.3, 53.5)

9.4 (0.9, 98.2)

Baseline (day 1) RAMRIS

 Synovitis

  Mean (SD)

6.4 (4.70)

10.5 (4.97)

  Median (min, max)

6.0 (0, 15)

10.0 (2, 20)

 Bone erosion

  Mean (SD)

11.5 (11.02)

16.5 (13.36)

  Median (min, max)

7.0 (1, 40)

16.0 (1, 54)

 Osteitis

  Mean (SD)

5.3 (7.97)

6.4 (9.61)

  Median (min, max)

1.0 (0, 28)

2.0 (0, 36)

Baseline (day 1) CARLOS

 Mean (SD)

4.7 (9.32)

6.0 (9.06)

 Median (min, max)

0 (0, 34)

1.5 (0, 36)

Baseline (day 1) Vectra DA

 Mean (SD)

50.8 (14.85)

50.9 (13.39)

 Median (min, max)

51.5 (21, 69)

49.0 (29, 89)

Baseline (day 1) HAQ-DI

 Mean (SD)

1.3 (0.79)

1.2 (0.61)

 Median (min, max)

1.6 (0.0, 2.3)

1.4 (0.0, 2.1)

Baseline (day 1) FACIT-Fatigue

 Mean (SD)

24.3 (9.92)

32.6 (10.18)

 Median (min, max)

23.5 (8, 50)

32.5 (16, 52)

  1. Data are expressed as mean (SD) unless otherwise stated
  2. aMinimum values are outside the inclusion criteria because minimum values for inclusion were assessed at screening, and these data represent data collected at the baseline visit (day 1)
  3. b.i.d., twice daily; BMI, body mass index; CARLOS, Cartilage Loss Scoring System; CRP, C-reactive protein; DAS28-CRP, disease activity score for 28 joints using CRP value; FACIT, Functional Assessment of Chronic Illness Therapy; HAQ-DI, Health Assessment Questionnaire-Disability Index; RA, rheumatoid arthritis; RAMRIS, Rheumatoid Arthritis MRI Scoring System; SD, standard deviation; t.i.d., three times daily; Vectra DA, Vectra disease activity
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us